BioCardia, Inc. Warrant
BCDAW
BCDAW was delisted on the 2nd of August, 2024.
2 hedge funds and large institutions have $52K invested in BioCardia, Inc. Warrant in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
4% more capital invested
Capital invested by funds: $50K → $52K (+$2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.26K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
1
Ladenburg Thalmann Financial Services
Miami,
Florida
| $51K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $1K | +$1.26K | +1,105 | New |
|
BCDAW Hedge Fund Activity: Q4 2019 in Review
2 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in BioCardia, Inc. Warrant (BCDAW) for Q4 2019, worth a combined $52K — up 4% from $50K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BCDAW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.26K.
- 2 institutional investors held BioCardia, Inc. Warrant (BCDAW) as of Q4 2019, up from 1 in Q3 2019.
- Funds reported $52K of BioCardia, Inc. Warrant stock for Q4 2019, up 4% quarter-over-quarter.
- 1 fund opened new BioCardia, Inc. Warrant positions in Q4 2019 and 0 closed out, a net change of +1 holder.
- The largest BioCardia, Inc. Warrant buyer in Q4 2019 was UBS Group, an estimated $1.26K added.
Based on aggregated 13F filings for Q4 2019.